2021 Future Medical Industry Summit, Dr. Xiao Xiao【Gene Therapy: Expansion from Rare Disease to Common Medicine】
From October 11 to 14, 2021, Shanghai held the first Bio-pharmaceutical Industry Week in China, "Shanghai International Bio-pharmaceutical Industry Week 2021 (IBIWS2021)". Relying on the bio-pharmaceutical industry park, international well-known enterprises and investment institutions and other industry parties, 20 forum activities have been held in Shanghai. As one of the key activities, the future Medical Industry Summit 2021 was held in Pudong Shangri-La Hotel from October 12 to 13, 2021.
With the theme of "In future, drive the new life", the summit brought together scientific experts and well-known entrepreneurs in the fields of small nucleic acid, mRNA drugs, cell and gene therapy, gene big data and medical technology, to look into the future development direction of innovative biomedicine and medical technology in various forms such as keynote speech, roundtable forum and closed-door meetings.
Dr. Xiao Xiao, Co-founder 、Chairman and CSO of Belief BioMed, delivered a speech on Gene therapy: The Expansion from Rare Disease to Common Medicine at the summit.
Biological medicine is one of the three leading industries of Shanghai, is also the important pillar of the Shanghai strategic emerging industries. At present the country is building biological medicine industrial cluster, Shanghai has become one of the most influential innovation highland of biomedical industry in China due to its relatively comprehensive industrial system, high degree of internationalization and strong R&D and innovation ability.
Same as 2020, the first half of 2021, the total financing of biomedicine still dominated the entire medical and health sector, which was about 191.8 billion RMB, more than the sum of digital health and devices. Biomedicine has always been in the tuyere of medical and health field, and its development must be inseparable from the support of policy. In 2020, the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) carried out a series of policy reforms on the clinical, review and prices of innovative drugs. The digital transformation of the global biomedical industry, especially in the development of new drugs, is accelerating, and the global is also increasingly investing in cutting-edge therapies such as cell and gene therapy.
Innovation and digitalization have become the main theme of the development of biomedical industry, whether it is policy or industry demand. In this wave, how to get rid of the floating clouds to peek into the essence and truly grasp the development opportunities may be the primary problem placed in front of all parties in the industry.
As a leading innovative pharmaceutical company, Belief BioMed integrates gene therapy, production platform and clinical technology. BBM has its own patents for a variety of AAV vectors, as well as dozens of new capsids with extremely specific tissue tropism. Its recombinant AAV packaging technology has been widely used in the field of AAV gene therapy. Additionally, the company has extremely rich research and development pipelines.
On August 6th, 2021, China’s National Medical Products Administration (NMPA) has cleared the IND (Investigational New Drug) application for Belief BioMed’s BBM-H901. This marks the first IND approval for AAV gene therapy for Hemophilia in China, and the first intravenous infusion gene therapy for rare diseases in China.
On September 28, 2021, the "Touchline Technology 2021 Annual List" was released at the BIC2021 3rd Asia Biopharmaceutical Innovation Summit. Believe BioMed was awarded the TOP10 cell & gene therapy drug companies with the most development potential.